Published 2023-08-01
“…Huilin Su,1– 3,* Weiwei Jiang,4,* Paul E Verweij,3,5 Li Li,2 Junhao Zhu,2 Jiande
Han,1 Min Zhu,2 Shuwen Deng6 1Department of Dermatology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People’s Republic of China; 2Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China; 3Department of Medical Microbiology and Center of Expertise in Mycology, Radboud University Medical Center, Nijmegen, the Netherlands; 4Department of Dermatology, Hospital affiliated to the 72nd Army of
Chinese PLA, Huzhou, People’s Republic of China; 5Department of Medical Microbiology and Center of Expertise in Mycology, CWZ Hospital, Nijmegen, the Netherlands; 6Department of Medical Microbiology, The People’s Hospital of SND, Suzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Shuwen Deng, Department of Medical Microbiology, The People’s Hospital of SND, Suzhou, People’s Republic of China, Email shuwen.deng@gmail.com Min Zhu, Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China, Email juneminmyco@126.comIntroduction: The emergence of resistance in Trichophyton rubrum to azoles and terbinafine has become increasingly evident in recent years, necessitating the development of novel antifungal drugs and the exploration of new indications for existing agents.Methods: In this study, we retrospectively evaluated the in vitro antifungal activity of 3 echinocandins (anidulafungin, caspofungin, and micafungin) against 73 clinical isolates of T. rubrum collected from a teaching hospital in Shanghai, China, using EUCAST E.DEF 9.3.1 with minor modification. …”
Get full text
Article